Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Levi-Schaffer Francesca


 Last updated December 2021 - School of Pharmacy

List of Publications

(1) Puzzovio PG, Levi-Schaffer F. The allergic effector unit: From basic science to drug-targetable mast cell–eosinophil interactions in patients. J Allergy Clin Immunol Pract 2021;9(10):3845-3846.

(2) Valiate BVS, Queiroz-Junior CM, Levi-Schaffer F, Galvão I, Teixeira MM. CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis. Immunology 2021;164(2):305-317.

(3) Gaur P, Rahimli Alekberli F, Karra L, Mankuta D, Ben-Zimra M, Levi-Schaffer F. Dexamethasone and CD300a activation display additive inhibitory effect on human and murine mast cell functions. Clin Exp Allergy 2021;51(10):1383-1386.

(4) Zoabi Y, Rahimli Alekberli F, Minai-Fleminger Y, Eliashar R, Levi-Schaffer F. CD48 Expression on Eosinophils in Nasal Polyps of Chronic Rhinosinusitis Patients. Int Arch Allergy Immunol 2021;182(10):962-970.

(5) Puzzovio PG, Levi-Schaffer F. Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis. Front Pharmacol 2021;12.

(6) Isaacson B, Baron M, Yamin R, Bachrach G, Levi-Schaffer F, Granot Z, et al. The inhibitory receptor CD300a is essential for neutrophil-mediated clearance of urinary tract infection in mice. Eur J Immunol 2021;51(9):2218-2224.

(7) Pahima H, Puzzovio PG, Levi-Schaffer F. A novel mast cell-dependent allergic peritonitis model. Clin Exp Immunol 2021;205(3):306-315.

(8) Levi-Schaffer F, de Marco A. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31. Br J Pharmacol 2021;178(17):3359-3372.

(9) Renz H, Bachert C, Berek C, Hamelmann E, Levi-Schaffer F, Raap U, et al. Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI. Scand J Immunol 2021;93(6).

(10) Ottman N, Barrientos-Somarribas M, Fyhrquist N, Alexander H, Wisgrill L, Olah P, et al. Microbial and transcriptional differences elucidate atopic dermatitis heterogeneity across skin sites. Allergy Eur J Allergy Clin Immunol 2021;76(4):1173-1187.

(11) Gangwar RS, Pahima H, Puzzovio PG, Levi-Schaffer F. Update on Eosinophil Interaction with Mast Cells: The Allergic Effector Unit. Methods Mol Biol 2021;2241:221-242.

(12) Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, et al. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy Eur J Allergy Clin Immunol 2021;76(1):90-113.

(13) Alexander SPH, Armstrong JF, Davenport AP, Davies JA, Faccenda E, Harding SD, et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol 2020;177(21):4942-4966.

(14) Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, et al. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacol Res 2020;158.

(15) Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, et al. AllergoOncology: Ultra-low IgE, a potential novel biomarker in cancer - A Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy 2020;10(1).

(16) Tavares LP, Peh HY, Tan WSD, Pahima H, Maffia P, Tiligada E, et al. Granulocyte-targeted therapies for airway diseases. Pharmacol Res 2020;157.

(17) Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, et al. The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. Immunology 2020;160(1):10-23.

(18) Levi-Schaffer F, Mankuta D. Omalizumab safety in pregnancy. J Allergy Clin Immunol 2020;145(2):481-483.

(19) Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, et al. Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun 2019;10(1).

(20) Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Invest Drugs 2019;28(11):931-940.

(21) Valiate BVS, Alvarez RU, Karra L, Queiroz-Júnior CM, Amaral FA, Levi-Schaffer F, et al. The immunoreceptor CD300a controls the intensity of inflammation and dysfunction in a model of Ag-induced arthritis in mice. J Leukocyte Biol 2019;106(4):957-966.

(22) Legrand F, Landolina N, Zaffran I, Emeh RO, Chen E, Klion AD, et al. Siglec-7 on peripheral blood eosinophils: Surface expression and function. Allergy Eur J Allergy Clin Immunol 2019;74(7):1257-1265.

(23) Karra L, Gangwar RS, Puzzovio PG, Fyhrquist N, Minai-Fleminger Y, Landolina N, et al. CD300a expression is modulated in atopic dermatitis and could influence the inflammatory response. Allergy Eur J Allergy Clin Immunol 2019;74(7):1377-1380.

(24) Pahima H, Puzzovio PG, Levi-Schaffer F. 2B4 and CD48: A powerful couple of the immune system. Clin Immunol 2019;204:64-68.

(25) Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, et al. AllergoOncology: Microbiota in allergy and cancer—A European Academy for Allergy and Clinical Immunology position paper. Allergy Eur J Allergy Clin Immunol 2019;74(6):1037-1051.

(26) Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. Allergy Eur J Allergy Clin Immunol 2019;74(3):432-448.

(27) Shamri R, Dubois G, Erpenbeck VJ, Mankuta D, Sandham DA, Levi-Schaffer F. Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells. Clin Exp Allergy 2019;49(2):255-257.

(28) Barnig C, Bezema T, Calder PC, Charloux A, Frossard N, Garssen J, et al. Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. Front Immunol 2019;10:1699.

(29) Karra L, Gangwar RS, Shamri R, Puzzovio PG, Cohen-Mor S, Levy BD, et al. Leukocyte CD300a Contributes to the Resolution of Murine Allergic Inflammation. J Immunol 2018;201(10):2998-3005.

(30) Levi-Schaffer F, Scheffel J. Dangerous liaisons in anaphylaxis. Sci 2018;362(6415):640-641.

(31) Erlich TH, Sharkia I, Landolina N, Assayag M, Goldberger O, Berkman N, et al. Modulation of allergic responses by mitochondrial STAT3 inhibitors. Allergy Eur J Allergy Clin Immunol 2018;73(11):2160-2171.

(32) Riccardi C, Levi-Schaffer F, Tiligada E. Preface. Immunopharmacol and Inflamm 2018:v-vi.

(33) Riccardi C, Levi-Schaffer F, Tiligada E. Immunopharmacology and inflammation. Immunopharmacology and Inflammation; 2018. p. 1-331.

(34) Tiligada E, Gerasimidou K, Levi-Schaffer F. Innovative drugs for allergies. Immunopharmacology and Inflammation; 2018. p. 309-321.

(35) Shefler I, Salamon P, Levi-Schaffer F, Mor A, Hershko AY, Mekori YA. MicroRNA-4443 regulates mast cell activation by T cell–derived microvesicles. J Allergy Clin Immunol 2018;141(6):2132-2141.e4.

(36) Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin Drug Saf 2018;17(4):429-435.

(37) Robida PA, Puzzovio PG, Pahima H, Levi-Schaffer F, Bochner BS. Human eosinophils and mast cells: Birds of a feather flock together. Immunol Rev 2018;282(1):151-167.

(38) Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D, et al. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy Eur J Allergy Clin Immunol 2018;73(2):328-340.

(39) Levi-Schaffer F, Mandelboim O. Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours. Trends Immunol 2018;39(2):112-122.

(40) Breuer O, Gangwar RS, Seaf M, Barhoum A, Kerem E, Levi-Schaffer F. Evaluation of soluble CD48 levels in patients with allergic and nonallergic asthma in relation to markers of type 2 and non-type 2 immunity: An observational study. J Immunol Res 2018;2018.

(41) Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res 2018;46(D1):D1091-D1106.

(42) Bulfone-Paus S, Nilsson G, Draber P, Blank U, Levi-Schaffer F. Positive and Negative Signals in Mast Cell Activation. Trends Immunol 2017;38(9):657-667.

(43) Rosenberg HF, Fryer AD, Munitz A, Bochner BS, Jacoby DB, Levi-Schaffer F, et al. In Memory and Celebration: Dr. James J. Lee. Clin Exp Allergy 2017;47(7):980-981.

(44) Sharkia I, Hadad Erlich T, Landolina N, Assayag M, Motzik A, Rachmin I, et al. Pyruvate dehydrogenase has a major role in mast cell function, and its activity is regulated by mitochondrial microphthalmia transcription factor. J Allergy Clin Immunol 2017;140(1):204-214.e8.

(45) Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, et al. AllergoOncology – the impact of allergy in oncology: EAACI position paper. Allergy Eur J Allergy Clin Immunol 2017;72(6):866-887.

(46) Gangwar RS, Minai-Fleminger Y, Seaf M, Gutgold A, Shikotra A, Barber C, et al. CD48 on blood leukocytes and in serum of asthma patients varies with severity. Allergy Eur J Allergy Clin Immunol 2017;72(6):888-895.

(47) Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol Ther 2017;170:37-63.

(48) Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F, Marone G. Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer. Front Med 2017;4(JUL).

(49) Braido F, Scichilone N, Lavorini F, Usmani OS, Dubuske L, Boulet LP, et al. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). World Allergy Organ J 2016;9(1):1-6.

(50) Seaf M, Ben-Zimra M, Mankuta D, Dayan N, Levi-Schaffer F. Papain Activates Human Mast Cells to Release Proinflammatory Mediators via its Enzymatic Activity. J Invest Dermatol 2016;136(7):1523-1525.

(51) Gangwar RS, Levi-Schaffer F. SCD48 is anti-inflammatory in Staphylococcus aureus Enterotoxin B-induced eosinophilic inflammation. Allergy Eur J Allergy Clin Immunol 2016;71(6):829-839.

(52) Gangwar RS, Friedman S, Seaf M, Levi-Schaffer F. Mast cells and eosinophils in allergy: Close friends or just neighbors. Eur J Pharmacol 2016;778:77-83.

(53) Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: From monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol 2016;173(9):1407-1424.

(54) Duev-Cohen A, Bar-On Y, Glasner A, Berhani O, Ophir Y, Levi-Schaffer F, et al. The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget 2016;7(11):13093-13105.

(55) Landolina N, Levi-Schaffer F. Monoclonal antibodies: The new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol 2016;173(5):793-803.

(56) Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016;9(1).

(57) Schmiedel D, Tai J, Levi-Schaffer F, Dovrat S, Mandelboim O. Human herpesvirus 6B downregulates expression of activating ligands during lytic infection to escape elimination by natural killer cells. J Virol 2016;90(21):9608-9617.

(58) Cho K, Clementi E, Levi-Schaffer F, Smalley KS, Radice S, Watts SW. Introducing a checklist for manuscript submission to Pharmacological Research. Pharmacol Res 2015;102:319-321.

(59) Cho K, Clementi E, Levi-Schaffer F, Smalley KSM, Radice S, Watts SW. Pharmacological research and precision cancer medicine: A call for manuscripts. Pharmacol Res 2015;102:308-309.

(60) Tiligada E, Ishii M, Riccardi C, Spedding M, Simon H-, Teixeira MM, et al. The expanding role of immunopharmacology: IUPHAR Review 16. Br J Pharmacol 2015;172(17):4217-4227.

(61) Karra L, Haworth O, Priluck R, Levy BD, Levi-Schaffer F. Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice. Mucosal Immunol 2015;8(4):852-862.

(62) Shamri R, Minai-Fleminger Y, Gangwar RS, Migalovich-Sheikhet H, Seaf M, Levi-Schaffer F. Author response to 'Staphylococcus aureus and primary lysis of eosinophils' by Dr Persson. Clin Exp Allergy 2015;45(2):490-491.

(63) Friedman S, Levi-Schaffer F. Substance p and eosinophils: An itchy connection. Exp Dermatol 2015;24(12):918-919.

(64) Landolina N, Gangwar RS, Levi-Schaffer F. Mast Cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: Implications for therapy. Adv Immunol 2015;125(1):41-85.

(65) Siebenhaar F, Falcone FH, Tiligada E, Hammel I, Maurer M, Sagi-Eisenberg R, et al. The search for mast cell and basophil models - Are we getting closer to pathophysiological relevance? Allergy Eur J Allergy Clin Immunol 2015;70(1):1-5.

(66) Elishmereni M, Fyhrquist N, Singh Gangwar R, Lehtimäki S, Alenius H, Levi-Schaffer F. Complex 2B4 Regulation of Mast Cells and Eosinophils in Murine Allergic Inflammation. J Invest Dermatol 2014;134(12):2928-2937.

(67) Minai-Fleminger Y, Gangwar RS, Migalovich-Sheikhet H, Seaf M, Leibovici V, Hollander N, et al. The CD48 receptor mediates Staphylococcus aureus human and murine eosinophil activation. Clin Exp Allergy 2014;44(11):1335-1346.

(68) Melo FR, Vita F, Berent-Maoz B, Levi-Schaffer F, Zabucchi G, Pejler G. Proteolytic histone modification by mast cell tryptase, a serglycin proteoglycan-dependent secretory granule protease. J Biol Chem 2014;289(11):7682-7690.

(69) Gangwar RS, Levi-Schaffer F. Eosinophils interaction with mast cells: The allergic effector unit. Methods Mol Biol 2014;1178:231-249.

(70) Landolina NAC, Levi-Schaffer F. Eosinophils as a pharmacological target for the treatment of allergic diseases. Curr Opin Pharmacol 2014;17(1):71-80.

(71) Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, et al. Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 2014;134(3):530-544.

(72) Erlich TH, Yagil Z, Kay G, Peretz A, Migalovich-Sheikhet H, Tshori S, et al. Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol 2014;134(2):460-469.e10.

(73) Efraim AHNB, Levi-Schaffer F. Roles of eosinophils in the modulation of angiogenesis. Chem Immunol Allergy 2014;99:138-154.

(74) Mizrahi S, Gibbs BF, Karra L, Ben-Zimra M, Levi-Schaffer F. Siglec-7 is an inhibitory receptor on human mast cells and basophils. J Allergy Clin Immunol 2014;134(1):230-233.e3.

(75) Medina VA, Coruzzi G, Lamas DJM, Massari N, Adami M, Levi-Schaffer F, et al. Histamine in cancer. Histamine H4 Receptor: A Novel Drug Target in Immunoregulation and Inflammation; 2013. p. 259-308.

(76) Ennis M, Ciz M, Dib K, Friedman S, Gangwar RS, Gibbs BF, et al. Histamine receptors and inflammatory cells. Histamine H4 Receptor: A Novel Drug Target in Immunoregulation and Inflammation; 2013. p. 103-143.

(77) Ben-Zimra M, Bachelet I, Seaf M, Gleich GJ, Levi-Schaffer F. Eosinophil major basic protein activates human cord blood mast cells primed with fibroblast membranes by integrin-β1. Allergy Eur J Allergy Clin Immunol 2013;68(10):1259-1268.

(78) Prussin C, Scott GD, Fryer AD, Schroeder S, Masterson JC, Fillon S, et al. Eosinophil Cell-Cell Communication. Eosinophils in Health and Disease; 2013. p. 329-390.

(79) Alam R, Levi-Schaffer F, Koenderman L, Munitz A, Bickham UR, Malter JS, et al. Eosinophil Signal Transduction. Eosinophils in Health and Disease; 2013. p. 167-227.

(80) Elishmereni M, Bachelet I, Ben-Efraim AHN, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy Eur J Allergy Clin Immunol 2013;68(2):171-179.

(81) Nissim Ben Efraim AH, Karra L, Ben-Zimra M, Levi-Schaffer F. The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy Eur J Allergy Clin Immunol 2013;68(3):397-401.

(82) Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol 2012;3(AUG).

(83) Draber P, Halova I, Levi-Schaffer F, Draberova L. Transmembrane adaptor proteins in the high-affinity IgE receptor signaling. Front Immunol 2012;2(JAN).

(84) Gibbs BF, Sabato V, Bridts CH, Ebo DG, Ben-Zimra M, Levi-Schaffer F. Expressions and inhibitory functions of CD300a receptors on purified human basophils. Exp Dermatol 2012;21(11):884-885.

(85) Micera A, Puxeddu I, Balzamino BO, Bonini S, Levi-Schaffer F. Chronic Nerve Growth Factor Exposure Increases Apoptosis in a Model of In Vitro Induced Conjunctival Myofibroblasts. PLoS ONE 2012;7(10).

(86) Sabato V, Verweij MM, Bridts CH, Levi-Schaffer F, Gibbs BF, De Clerck LS, et al. CD300a is expressed on human basophils and seems to inhibit IgE/FcεRI-dependent anaphylactic degranulation. Cytometry Part B Clin Cytometry 2012;82 B(3):132-138.

(87) Gibbs BF, Levi-Schaffer F. H4 receptors in mast cells and basophils: A new therapeutic target for allergy? Front Biosci 2012;17(2):430-437.

(88) Stoyanov E, Uddin M, Mankuta D, Dubinett SM, Levi-Schaffer F. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer 2012;75(1):38-44.

(89) Cohen S, Efraim ANB, Levi-Schaffer F, Eliashar R. The effect of hypoxia and cycloxygenase inhibitors on nasal polyp derived fibroblasts. Am J Otolaryngol Head Neck Med Surg 2011;32(6):564-573.

(90) Karra L, Levi-Schaffer F. Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv Exp Med Biol 2011;716:143-159.

(91) Berkman N, Levi-Schaffer F. Profibrotic and Angiogenic Factors in Asthma. Inflammation and Allergy Drug Design; 2011. p. 237-252.

(92) Shpacovitch VM, Feld M, Holzinger D, Kido M, Hollenberg MD, Levi-Schaffer F, et al. Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes. Immunology 2011;133(3):329-339.

(93) Berent-Maoz B, Gur C, Vita F, Soranzo MR, Zabucchi G, Levi-Schaffer F. Influence of FAS on murine mast cell maturation. Ann Allergy Asthma Immunol 2011;106(3):239-244.

(94) Elishmereni M, Alenius HT, Bradding P, Mizrahi S, Shikotra A, Minai-Fleminger Y, et al. Physical interactions between mast cells and eosinophils: A novel mechanism enhancing eosinophil survival in vitro. Allergy Eur J Allergy Clin Immunol 2011;66(3):376-385.

(95) Pickholtz E, Admon D, Izhar U, Berkman N, Levi-Schaffer F. Dexamethasone and salbutamol stimulate human lung fibroblast proliferation. World Allergy Organ J 2011;4(12):249-256.

(96) Elishmereni M, Levi-Schaffer F. CD48: A co-stimulatory receptor of immunity. Int J Biochem Cell Biol 2011;43(1):25-28.

(97) Amer R, Rabinowich L, Maftsir G, Puxeddu I, Levi-Schaffer F, Solomon A. Mycophenolic acid suppresses human pterygium and normal tenon fibroblast proliferation in vitro. Br J Ophthalmol 2010;94(10):1373-1377.

(98) Minai-Fleminger Y, Elishmereni M, Vita F, Soranzo MR, Mankuta D, Zabucchi G, et al. Ultrastructural evidence for human mast cell-eosinophil interactions in vitro. Cell Tissue Res 2010;341(3):405-415.

(99) Lankry D, Simic H, Klieger Y, Levi-Schaffer F, Jonjic S, Mandelboim O. Expression and function of CD300 in NK cells. J Immunol 2010;185(5):2877-2886.

(100) Nissim Ben Efraim AH, Eliashar R, Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin Mol Allergy 2010;8.

(101) Viau E, Levi-Schaffer F, Peccia J. Respiratory toxicity and inflammatory response in human bronchial epithelial cells exposed to biosolids, animal manure, and agricultural soil particulate matter. Environ Sci Technol 2010;44(8):3142-3148.

(102) Berent-Maoz B, Salemi S, Mankuta D, Simon H-, Levi-Schaffer F. Human mast cells express intracellular TRAIL. Cell Immunol 2010;262(2):80-83.

(103) Puxeddu I, Berkman N, Ribatti D, Bader R, Haitchi HM, Davies DE, et al. Osteopontin is expressed and functional in human eosinophils. Allergy Eur J Allergy Clin Immunol 2010;65(2):168-174.

(104) Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N. Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010;104(1):66-72.

(105) Elishmereni M, Levi-Schaffer F. Skin Disorders of Inflammation and Immune Suppression in Young and Elder: A Special Role for Mast Cells. Skin Aging Handbook; 2009. p. 105-128.

(106) Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy 2009;39(12):1815-1821.

(107) Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Curr Opin Immunol 2009;21(6):708-714.

(108) Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: The two key effector cells in allergic inflammation. Inflamm Res 2009;58(10):631-638.

(109) Nissim Ben Efraim AH, Munitz A, Sherman Y, Mazer BD, Levi-Schaffer F, Eliashar R. Efficient purification of eosinophils from human tissues: A comparative study. J Immunol Methods 2009;343(2):91-96.

(110) Puxeddu I, Berkman N, Nissim Ben Efraim AH, Davies DE, Ribatti D, Gleich GJ, et al. The role of eosinophil major basic protein in angiogenesis. Allergy Eur J Allergy Clin Immunol 2009;64(3):368-374.

(111) Levi-Schaffer F, Eliashar R. Mast cell stabilizing properties of antihistamines. J Invest Dermatol 2009;129(11):2549-2551.

(112) Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis - A double-edged sword. Ann Med 2008;40(8):606-621.

(113) Ben-Yehuda C, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Airway eosinophil accumulation and eotaxin-2/CCL24 expression following allergen challenge in BALB/c mice. Exp Lung Res 2008;34(8):467-479.

(114) Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, Moses AE, Levi-Schaffer F. Human mast cell activation by Staphylococcus aureus: Interleukin-8 and tumor necrosis factor alpha release and the role of toll-like receptor 2 and CD48 molecules. Infect Immun 2008;76(10):4489-4497.

(115) Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol 2008;180(9):6064-6069.

(116) Elishmereni M, Bachelet I, Levi-Schaffer F. DNAM-1: An amplifier of immune responses as a therapeutic target in various disorders. Curr Opin Invest Drugs 2008;9(5):491-496.

(117) Berent-Maoz B, Salemi S, Mankuta D, Simon H-, Levi-Schaffer F. TRAIL mediated signaling in human mast cells: The influence of IgE-dependent activation. Allergy Eur J Allergy Clin Immunol 2008;63(3):333-340.

(118) Nissim Ben Efraim AH, Levi-Schaffer F. Review: Tissue remodeling and angiogenesis in asthma: The role of the eosinophil. Ther Adv Respir Dis 2008;2(3):163-171.

(119) Salamon P, Shoham NG, Puxeddu I, Paitan Y, Levi-Schaffer F, Mekori YA. Human mast cells release oncostatin M on contact with activated T cells: Possible biologic relevance. J Allergy Clin Immunol 2008;121(2):448-455.e5.

(120) Kohan M, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling. Clin Exp Allergy 2007;37(10):1444-1454.

(121) Bachelet I, Levi-Schaffer F. Mast cells as effector cells: a co-stimulating question. Trends Immunol 2007;28(8):360-365.

(122) Micera A, Lambiase A, Stampachiacchiere B, Bonini S, Bonini S, Levi-Schaffer F. Nerve growth factor and tissue repair remodeling: trkANGFR and p75NTR, two receptors one fate. Cytokine Growth Factor Rev 2007;18(3-4):245-256.

(123) Munitz A, Levi-Schaffer F. Inhibitory receptors on eosinophils: A direct hit to a possible Achilles heel? J Allergy Clin Immunol 2007;119(6):1382-1387.

(124) Munitz A, Bachelet I, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 Is critically involved in allergic eosinophilic airway inflammation. Am J Respir Crit Care Med 2007;175(9):911-918.

(125) Munitz A, Bachelet I, Levi-Schaffer F. CD48 as a novel target in asthma therapy. Recent Pat Inflamm Allergy Drug Discov 2007;1(1):9-12.

(126) Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 2006;118(5):1082-1089.

(127) Micera A, Lambiase A, Puxeddu I, Aloe L, Stampachiacchiere B, Levi-Schaffer F, et al. Nerve growth factor effect on human primary fibroblastic-keratocytes: Possible mechanism during corneal healing. Exp Eye Res 2006;83(4):747-757.

(128) Bachelet I, Munitz A, Mankutad D, Levi-Schaffer F. Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): A novel interface in the allergic process. J Biol Chem 2006;281(37):27190-27196.

(129) Bachelet I, Levi-Schaffer F, Mekori YA. Mast Cells: Not Only in Allergy. Immunol Allergy Clin North Am 2006;26(3):407-425.

(130) Munitz A, Bachelet I, Eliashar R, Khodoun M, Finkelman FD, Rothenberg ME, et al. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol 2006;177(1):77-83.

(131) Bachelet I, Munitz A, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 2006;117(6):1314-1320.

(132) Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 2006;107(5):1996-2003.

(133) Berent-Maoz B, Piliponsky AM, Daigle I, Simon H-, Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006;176(4):2272-2278.

(134) Bachelet I, Munitz A, Levi-Schaffer F. Co-culture of mast cells with fibroblasts: a tool to study their crosstalk. Methods Mol Biol 2006;315:295-317.

(135) Puxeddu I, Bader R, Piliponsky AM, Reich R, Levi-Schaffer F, Berkman N. The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol 2006;117(1):103-110.

(136) Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 2005;175(12):7989-7995.

(137) Solomon A, Wajngarten M, Alviano F, Anteby I, Elchalal U, Pe'er J, et al. Suppression of inflammatory and fibrotic responses in allergic inflammation by the amniotic membrane stromal matrix. Clin Exp Allergy 2005;35(7):941-948.

(138) Garbuzenko E, Berkman N, Puxeddu I, Kramer M, Nagler A, Levi-Schaffer F. Erratum: Mast cells induce activation of human lung fibroblasts in-vitro (Experimental Lung Research 30, 8 (705-721)). Exp Lung Res 2005;31(6):651.

(139) Eliashar R, Levi-Schaffer F. The role of the eosinophil in nasal diseases. Curr Opin Otolaryngol Head Neck Surg 2005;13(3):171-175.

(140) Micera A, Puxeddu I, Lambiase A, Antonelli A, Bonini S, Aloe L, et al. The pro-fibrogenic effect of nerve growth factor on conjunctival fibroblasts is mediated by transforming growth factor-β. Clin Exp Allergy 2005;35(5):650-656.

(141) Uings I, Puxeddu I, Temkin V, Smith SJ, Fattah D, Ray KP, et al. Effects of dexamethasone on TNF-alpha-induced released of cytokines from purified human blood eosinophils. Clin Mol Allergy 2005;3.

(142) Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005;37(3):628-636.

(143) Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005;116(3):531-536.

(144) Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon H-, et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 2005;174(1):110-118.

(145) Micera A, Lambiase A, Aloe L, Bonini S, Levi-Schaffer F, Bonini S. Nerve growth factor involvement in the visual system: Implications in allergic and neurodegenerative diseases. Cytokine Growth Factor Rev 2004;15(6):411-417.

(146) Garbozenko E, Puxeddu I, Levi-Schaffer F, Berkman N, Kramer M, Nagleir A. Mast cells induce activation of human lung fibroblasts in vitro. Exp Lung Res 2004;30(8):705-721.

(147) Puxeddu I, Lack G, Smith SJ, Levi-Schaffer F. Reduced eosinophil pro-fibrogenic effect in severe childhood asthma compared to mild disease: An effect of corticosteroids? Pediatr Pulmonol 2004;38(3):222-228.

(148) Xu X, Rivkind A, Pikarsky A, Pappo O, Bischoff SC, Levi-Schaffer F. Mast cells and eosinophils have a potential profibrogenic role in crohn disease. Scand J Gastroenterol 2004;39(5):440-447.

(149) Bischoff SC, Schwengberg S, Lorentz A, Manns MP, Bektas H, Sann H, et al. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterol Motil 2004;16(2):185-193.

(150) Munitz A, Levi-Schaffer F. Eosinophils: 'New' roles for 'old' cells. Allergy Eur J Allergy Clin Immunol 2004;59(3):268-275.

(151) Fraenkel S, Puxeddu I, Levi-Schaffer F. Immune Effector Cells: Mast Cells and Eosinophils? Pediatr Pulmonol 2004;37(SUPPL. 26):42-44.

(152) Temkin V, Aingorn H, Puxeddu I, Goldshmidt O, Zcharia E, Gleich GJ, et al. Eosinophil major basic protein: First identified natural heparanase-inhibiting protein. J Allergy Clin Immunol 2004;113(4):703-709.

(153) Puxeddu I, Levi-Schaffer F. Mast cells and eosinophils: The "hallmark" of asthma. Paediatr Respir Rev 2004;5(SUPPL. A):S31-S34.

(154) Sellge G, Lorentz A, Gebhardt T, Levi-Schaffer F, Bektas H, Manns MP, et al. Human Intestinal Fibroblasts Prevent Apoptosis in Human Intestinal Mast Cells by a Mechanism Independent of Stem Cell Factor, IL-3, IL-4, and Nerve Growth Factor. J Immunol 2004;172(1):260-267.

(155) Munitz A, Piliponsky AM, Levi-Schaffer F. IgE-independent activation of human mast cells indicates their role in the late phase reaction of allergic inflammation. Cell Tissue Bank 2003;4(1):25-28.

(156) Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is the physiological function of mast cells? Introduction. Exp Dermatol 2003;12(6):886.

(157) Temkin V, Pickholtz D, Levi-Schaffer F. Tumor necrosis factors in a murine model of allergic peritonitis: Effects on eosinophil accumulation and inflammatory mediators' release. Cytokine 2003;24(3):74-80.

(158) Solomon A, Puxeddu I, Levi-Schaffer F. Fibrosis in ocular allergic inflammation: Recent concepts in the pathogenesis of ocular allergy. Curr Opin Allergy Clin Immunol 2003;3(5):389-393.

(159) Roberts G, Patel N, Levi-Schaffer F, Habibi P, Lack G. Food allergy as a risk factor for life-threatening asthma in childhood: A case-controlled study. J Allergy Clin Immunol 2003;112(1):168-174.

(160) Bonini S, Lambiase A, Lapucci G, Properzi F, Bresciani M, Bracci Laudiero ML, et al. Erratum: Nerve growth factor and asthma (Allergy: European Journal of Allergy and Clinical Immunology (2002) 57:SUPPL 72 (13)). Allergy Eur J Allergy Clin Immunol 2003;58(4):366.

(161) Simon H-, Plötz S, Simon D, Seitzer U, Braathen LR, Menz G, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 2003;33(4):834-839.

(162) Levi-Schaffer F, Piliponsky AM. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol 2003;24(4):158-161.

(163) Piliponsky AM, Gleich GJ, Nagler A, Bar I, Levi-Schaffer F. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood 2003;101(5):1898-1904.

(164) Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. Mast cells in allergy and beyond. Int J Biochem Cell Biol 2003;35(12):1601-1607.

(165) Micera A, Puxeddu I, Aloe L, Levi-Schaffer F. New insights on the involvement of Nerve Growth Factor in allergic inflammation and fibrosis. Cytokine Growth Factor Rev 2003;14(5):369-374.

(166) A single-cell maturation process analysis under cell-to-cell interacting system by MALDI-TOF mass spectrometry. Proceedings 50th ASMS Conference on Mass Spectrometry and Allied Topics; 2002.

(167) Piliponsky AM, Gleich GJ, Bar I, Levi-Schaffer F. Effects of eosinophils on mast cells: A new pathway for the perpetuation of allergic inflammation. Mol Immunol 2002;38(16-18):1369-1372.

(168) Levi-Schaffer F, Temkin V, Simon H-, Kettman J-, Frey J-, Lefkovits I. Proteomic analysis of human eosinophil activation mediated by mast cells, granulocyte macrophage colony stimulating factor and tumor necrosis factor alpha. Proteomics 2002;2(11):1616-1626.

(169) Xu X, Rivkind A, Pappo O, Pikarsky A, Levi-Schaffer F. Role of mast cells and myofibroblasts in human peritoneal adhesion formation. Ann Surg 2002;236(5):593-601.

(170) Phipps S, Ying S, Wangoo A, Ong Y-, Levi-Schaffer F, Kay AB. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 2002;169(8):4604-4612.

(171) Temkin V, Kantor B, Weg V, Hartman M-, Levi-Schaffer F. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 2002;169(5):2662-2669.

(172) Levi-Schaffer F, Micera A, Zamir E, Mechoulam H, Puxeddu I, Piliponsky AM, et al. Nerve growth factor and eosinophils in inflamed juvenile conjunctival nevus. Invest Ophthalmol Vis Sci 2002;43(6):1850-1856.

(173) Smith SJ, Piliponsky AM, Hartman M-, Levi-Schaffer F. Stem cell factor - A possible paradigm between mast cells, eosinophils, and fibroblasts. Allergy Clin Immunol Int 2002;14(2):52-59.

(174) Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: A direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002;32(2):237-246.

(175) Xu X, Weksler-Zangen S, Pikarsky A, Pappo O, Wengrower D, Bischoff SC, et al. Mast cells involvement in the inflammation and fibrosis development of the TNBS-induced rat model of colitis. Scand J Gastroenterol 2002;37(3):330-337.

(176) Zamir E, Mechoulam H, Micera A, Levi-Schaffer F, Pe'er J. Inflamed juvenile conjunctival naevus: Clinicopathological characterisation. Br J Ophthalmol 2002;86(1):28-30.

(177) Xu X, Pappo O, Garbuzenko E, Bischoff SC, Rivkind A, Levi-Schaffer F. Mast cell dynamics and involvement in the development of peritoneal adhesions in the rat. Life Sci 2002;70(8):951-967.

(178) Shimizu M, Levi-Schaffer F, Ojima N, Shingaki T, Masujima T. A Single-Cell Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass-Spectroscopic Assay of the Cell-Maturation Process. Anal Sci 2002;18(2):107-108.

(179) Smith SJ, Piliponsky AM, Rosenhead F, Elchalal U, Nagler A, Levi-Schaffer F. Dexamethasone inhibits maturation, cytokine production and FcεRI expression of human cord blood-derived mast cells. Clin Exp Allergy 2002;32(6):906-913.

(180) Puxeddu I, Levi-Schaffer F. Mast cells and tissue remodeling. Rev Fr Allergol Immunol Clin 2002;42(1):16-18.

(181) Levi-Schaffer F, Pe'Er J. Mast cells and angiogenesis. Clin Exp Allergy 2001;31(4):521-524.

(182) Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. Biomaterials 2001;22(22):3053-3059.

(183) Hershko AY, Dranitzki Z, Ulmanski R, Levi-Schaffer F, Naparstek Y. Constitutive hyperhistaminaemia: A possible mechanism for recurrent anaphylaxis. Scand J Clin Lab Invest 2001;61(6):449-452.

(184) Temkin V, Levi-Schaffer F. Mechanism of tumour necrosis factor alpha mediated eosinophil survival. Cytokine 2001;15(1):20-26.

(185) Hoenstein R, Admon D, Solomon A, Norris A, Moqbel R, Levi-Schaffer F. Interleukin-2 activates human peripheral blood eosinophils. Cell Immunol 2001;210(2):116-124.

(186) Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci U S A 2001;98(11):6162-6167.

(187) Levi-Schaffer F, Micera A, Maquart FX, Aloe L. Nerve growth factor is produced by human fibroblasts and modulates them: Role of nerve growth factor in tissue repair. Int Arch Allergy Immunol 2001;124(1-3):279-281.

(188) Hartman M-, Piliponsky AM, Temkin V, Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood 2001;97(4):1086-1091.

(189) Solomon A, Pe'er J, Levi-Schaffer F. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol 2001;1(5):477-482.

(190) Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F. Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: A possible role for mast cells in late-phase allergic reactions. J Allergy Clin Immunol 2001;107(6):993-1000.

(191) Piliponsky AM, Levi-Schaffer F. Regulation of apoptosis in mast cells. Apoptosis 2000;5(5):435-441.

(192) Simon H-, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000;5(5):415-418.

(193) Simon H-, Weber M, Becker E, Zilberman Y, Blaser K, Levi-Schaffer F. Eosinophils maintain their capacity to signal and release eosinophil cationic protein upon repetitive stimulation with the same agonist. J Immunol 2000;165(7):4069-4075.

(194) Berton A, Levi-Schaffer F, Emonard H, Garbuzenko E, Gillery P, Maquart F-. Activation of fibroblasts in collagen lattices by mast cell extract: A model of fibrosis. Clin Exp Allergy 2000;30(4):485-492.

(195) Solomon A, Shmilowich R, Shasha D, Frucht-Pery J, Pe'er J, Bonini S, et al. Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro. Invest Ophthalmol Vis Sci 2000;41(5):1038-1044.

(196) Levi-Schaffer F, Slovik D, Armetti L, Pickholtz D, Touitou E. Activation and inhibition of mast cells degranulation affect their morphometric parameters. Life Sci 2000;66(21):PL283-PL290.

(197) Smith SJ, Ying S, Meng Q, Sullivan MHF, Barkans J, Kon OM, et al. Blood eosinophils from atopic donors express messenger RNA for the α, β, and γ subunits of the high-affinity IgE receptor (FcεRI) and intracellular, but not cell surface, α subunit protein. J Allergy Clin Immunol 2000;105(2 II):309-317.

(198) Smith SJ, Levi-Schaffer F. Mast cell-eosinophil-fibroblast crosstalk in allergic inflammation. Chem Immunol 2000;78:81-92.

(199) Levi-Schaffer F, Garbuzenko E, Rubin A, Reich R, Pickholz D, Gillery P, et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: A role for transforming growth factor β (TGF-β). Proc Natl Acad Sci U S A 1999;96(17):9660-9665.

(200) Levi-Schaffer F. Cross-talk between mast cells and eosinophils. Allergy Eur J Allergy Clin Immunol Suppl 1999;54(58):36-38.

(201) Bonini S, Lambiase A, Levi-Schaffer F, Aloe L. Nerve growth factor: An important molecule in allergic inflammation and tissue remodelling. Int Arch Allergy Immunol 1999;118(2-4):159-162.

(202) Piliponsky AM, Pickholtz D, Gleich GJ, Levi-Schaffer F. Eosinophils activate mast cells to release histamine. Int Arch Allergy Immunol 1999;118(2-4):202-203.

(203) Armetti L, Admon D, Solomon A, Levi-Schaffer F. Mast cells and eosinophils - Their role in tissue remodeling. Allergy Clin Immunol Int 1999;11(1):22-28.

(204) Walsh GM, Dewson G, Wardlaw AJ, Levi-Schaffer F, Moqbel R. A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. J Immunol Methods 1998;217(1-2):153-163.

(205) Simon H-, Yousefi S, Dibbert B, Hebestreit H, Weber M, Branch DR, et al. Role for tyrosine phosphorylation and lyn tyrosine kinase in fas receptor-mediated apoptosis in eosinophils. Blood 1998;92(2):547-557.

(206) Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: Role of TNF-α and granulocyte-macrophage colony-stimulating factor. J Immunol 1998;160(11):5554-5562.

(207) Lacy P, Levi-Schaffer F, Mahmudi-Azer S, Bablitz B, Hagen SC, Velazquez J, et al. Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon γ. Blood 1998;91(7):2508-2516.

(208) Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, et al. Halofuginone-an inhibitor of collagen type I synthesis-prevents postoperative formation of abdominal adhesions. Ann Surg 1998;227(4):575-582.

(209) Rubinchik E, Shalit M, Levi-Schaffer F. Responsiveness of human skin mast cells to repeated activation: An in vitro study. Allergy Eur J Allergy Clin Immunol 1998;53(1):14-19.

(210) Solomon A, Aloe L, Pe'Er J, Pery JF-, Bonini S, Bonini S, et al. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 1998;102(3):454-460.

(211) Simon H-, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K. Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27(12):3536-3539.

(212) Levi-Schaffer F, Weg VB. Mast cells, eosinophils and fibrosis. CLIN EXP ALLERGY SUPPL 1997;27(1):64-70.

(213) Levi-Schaffer F, Segal V, Barak V, Rubinchik E, Nagler A. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease. Exp Hematol 1997;25(3):238-245.

(214) Levi-Schaffer F, Goldenhersh MA, Segal V, Nagler A. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 1997;19(8):823-828.

(215) Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99(2):155-160.

(216) Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone. Biochem Pharmacol 1996;52(7):1057-1063.

(217) Kupietzky A, Levi-Schaffer F. The role of mast cell-derived histamine in the closure of an in vitro wound. Inflamm Res 1996;45(4):176-180.

(218) Rubinchik E, Levi-Schaffer F. Interleukin-2 inhibits 3T3 fibroblast proliferation. Life Sci 1996;58(18):1509-1517.

(219) Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 1996;87(1):155-161.

(220) Solomon A, Levi-Schaffer F. Mast cells beyond allergy: Their role in fibrotic conditions. BIOMED REV 1996;6:69-74.

(221) Levi-Schaffer F, Dayan N, Touitou E. Diethylene glycol monoethyl ether (Transcutol®) displays antiproliferative properties alone and in combination with xanthines. Skin Pharmacol Physiol 1996;9(1):53-59.

(222) Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone. J Invest Dermatol 1996;106(1):84-88.

(223) Levi-Schaffer F, Shani J, Politi Y, Rubinchik E, Brenner S. Inhibition of proliferation of psoriatic and healthy fibroblasts in cell culture by selected dead-sea salts. Pharmacology 1996;52(5):321-328.

(224) Nagler A, Goldenhersh MA, Levi-Schaffer F, Bystryn J-, Klaus SN. Total leucoderma: A rare manifestation of cutaneous chronic graft-versus-host disease. Br J Dermatol 1996;134(4):780-783.

(225) Levi-Schaffer F, Lacy P, Severs NJ, Newman TM, North J, Gomperts B, et al. Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils. Blood 1995;85(9):2579-2586.

(226) Levi-Schaffer F, Baram D, Segal V, Garbuzenko E, Lew S, Mekori YA. Prostaglandin E2 production by chronic graft-versus-host disease dermal fibroblasts. Immunol Lett 1995;48(1):11-15.

(227) Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995;25(9):896-902.

(228) Levi-Schaffer F, Rubinchik E. Mast cell role in fibrotic diseases. Isr J Med Sci 1995;31(7):450-453.

(229) Devalia JL, Davies RJ, Befus AD, Bissonnette EY, Levi-Schaffer F, Rainey DK, et al. Inhibitory effects of nedocromil sodium on cytokine production from mast and epithelial cells. Int Arch Allergy Immunol 1995;107(1-3):417.

(230) Levi-Schaffer F, Kelav-Appelbaum R, Rubinchik E. Human foreskin mast cell viability and functional activity is maintained ex vivo by coculture with fibroblasts. Cell Immunol 1995;162(2):211-216.

(231) Nagler A, Segal V, Slavin S, Levi-Schaffer F. Ketotifen therapy in chronic graft-versus-host disease (cGVHD): Effect on mast cells and fibroblasts. Clin Exp Immunol 1995;100(3):529-535.

(232) Levi-Schaffer F, Klapholz L, Weinrauch L, Shalit M. Coculture of mast cells with psoriatic fibroblasts: an experimental system for studying the two cell interactions. J Eur Acad Dermatol Venereol 1995;4(3):230-234.

(233) Levi-Schaffer F, Rubinchik E. Activated mast cells are fibrogenic for 3T3 fibroblasts. J Invest Dermatol 1995;104(6):999-1003.

(234) Levi-Schaffer F. Mast cell/fibroblast interactions in health and disease. Chem Immunol 1995;61:161-185.

(235) Rubinchik E, Norris A, Levi-Schaffer F. Modulation of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Int J Immunopharmacol 1995;17(7):563-570.

(236) Levi-Schaffer F, Rubinchik E. Mast cell/fibroblast interactions. Clin Exp Allergy 1994;24(11):1016-1021.

(237) Touitou E, Levi-Schaffer F, Dayan N, Alhaique F, Riccieri F. Modulation of caffeine skin delivery by carrier design: liposomes versus permeation enhancers. Int J Pharm 1994;103(2):131-136.

(238) Moqbel R, Levi-Schaffer F, Barry Kay A. Cytokine generation by eosinophils. J Allergy Clin Immunol 1994;94(6 PART 2):1183-1188.

(239) Brenner T, Soffer D, Shalit M, Levi-Schaffer F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci 1994;122(2):210-213.

(240) Rubinchik E, Levi-Schaffer F. Mast cells and fibroblasts: two interacting cells. Int J Clin Lab Res 1994;24(3):139-142.

(241) Vourka-Karussis U, Levi-Schaffer F, Slavin S. Investigations on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant human interleukin-2. Exp Hematol 1993;21(1):93-97.

(242) O'Byrne P, Schmekel B, Kapp A, Ahlstedt S, Wahn U, Fabbri L, et al. General discussion. ALLERGY EUR J ALLERGY CLIN IMMUNOL SUPPL 1993;48(17):110-111.

(243) Shalit M, Brenner T, Shohami E, Levi-Schaffer F. Interaction between mast cells and glial cells: an in vitro study. J Neuroimmunol 1993;43(1-2):195-199.

(244) Levi-Schaffer F, Shalit M. Proliferation and functional responses of bone marrow-derived mast cells after activation. Cell Immunol 1993;148(2):435-443.

(245) Levi-Schaffer F, Segal V, Nagler A. Mast cell and fibroblast functional activity are affected by immunocompetent cells in chronic grafts-vs.-host disease. Int Arch Allergy Immunol 1992;99(2-4):238-241.

(246) Stevens RL, Somerville LL, Sewell D, Swafford JR, Caulfield JP, Levi‐Schaffer F, et al. Serosal mast cells maintain their viability and promote the metabolism of cartilage proteoglycans when cocultured with chondrocytes. Arthritis Rheum 1992;35(3):325-335.

(247) Levi-Schaffer F, Segal V, Baram D, Mekori YA. Effect of coculture of rodent mast cells with murine chronic graft-versus-host disease (cGVHD)-derived fibroblasts. J Allergy Clin Immunol 1992;89(2):501-509.

(248) Shalit M, Riesel-Yaron N, Levi-Schaffer F. Nedocromil sodium modulates the function of long-term rat peritoneal mast cell cultures. Pharmacol Res 1992;26(3):293-303.

(249) Levi-Schaffer F, Riesel N, Soffer D, Abramsky O, Brenner T. Mast cell activity in experimental allergic encephalomyelitis. Mol Chem Neuropathol 1991;15(2):173-184.

(250) Touitou E, Levi-Schaffer F, Shaco-Ezra N, Ben-Yossef R, Fabin B. Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation. Int J Pharm 1991;70(1-2):159-166.

(251) Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F. Desferal (desferrioxamine)-A novel activator of connective tissue-type mast cells. J Allergy Clin Immunol 1991;88(6):854-860.

(252) Levi-Schaffer F, Segal V, Mekori YA, Claman HN, Hammel I. Morphological evidence for chronic mast cell activation after prolonged exposure with supernatants from chronic graft-versus-host splenocytes. Immunol Lett 1991;27(1):13-18.

(253) Levi-Schaffer F, Shalit M. Long-term cultures of mast cells: a new model for studying the allergic response. Pharmacol Res 1991;24(4):307-317.

(254) Levi-Schaffer F, Touitou E. Xanthines inhibit 3T3 fibroblast proliferation. Skin Pharmacol 1991;4(4):286-290.

(255) Levi-Schaffer F, Klapholz L, Kupietzky A, Weinrauch L, Shalit M, Okon E. Increased numbers of mast cells in pemphigus vulgaris skin lesions. A histochemical study. ACTA DERM -VENEREOL 1991;71(3):269-271.

(256) Levi-Schaffer F, Segal V, Shalit M. Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts. Immunology 1991;72(2):174-180.

(257) Levi-Schaffer F, Mekori YA, Segal V, Claman HN. Histamine release from mouse and rat mast cells cultured with supernatants from chronic murine graft-vs-host splenocytes. Cell Immunol 1990;127(1):146-158.

(258) Levi‐Schaffer F, Riesel‐Yaron N. Effects of prolonged incubation of rat peritoneal mast cells with compound 48/80. Eur J Immunol 1990;20(12):2609-2613.

(259) Shalit M, Levi-Schaffer F. Auranofin inhibits histamine release from rat peritoneal mast cells. Int J Immunopharmacol 1990;12(4):403-407.

(260) Levi-Schaffer F, Kupietzky A. Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound. Exp Cell Res 1990;188(1):42-49.

(261) Levi-Schaffer F, Gare M, Shalit M. Unresponsiveness of rat peritoneal mast cells to immunologic reactivation. J Immunol 1990;145(10):3418-3424.

(262) Levi-Schaffer F, Bar-Shavit Z. Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. Immunology 1990;69(1):145-149.

(263) Levi-Schaffer F, Shatitb M. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. Int Arch Allergy Immunol 1989;90(4):352-357.

(264) Levi-Schaffer F, Riesel N. In vitro regeneration of activated rat peritoneal mast cells cocultured with 3T3 fibroblasts. Cell Immunol 1989;119(1):30-40.

(265) Katz HR, Dayton ET, Levi-Schaffer F, Benson AC, Austen KF, Stevens RL. Coculture of mouse IL-3-dependent mast cells with 3T3 fibroblasts stimulates synthesis of globopentaosylceramide (Forssman glycolipid) by fibroblasts and surface expression on both populations. J Immunol 1988;140(9):3090-3097.

(266) Dayton ET, Pharr P, Ogawa M, Serafin WE, Austen KF, Levi-Schaffer F, et al. 3T3 fibroblasts induce cloned interleukin 3-dependent mouse mast cells to resemble connective tissue mast cells in granular constituency. Proc Natl Acad Sci U S A 1988;85(2):569-572.

(267) Levi-Schaffer F, Dayton ET, Austen KF, Hein A, Caulfield JP, Gravallese PM, et al. Mouse bone marrow-derived mast cells cocultured with fibroblasts. Morphology and stimulation-induced release of histamine, leukotriene B4, leukotriene C4, and prostaglandin D2. J Immunol 1987;139(10):3431-3441.

(268) Levi-Schaffer F, Austen KF, Caulfield JP, Hein A, Gravallese PM, Stevens RL. Co-culture of human lung-derived mast cells with mouse 3T3 fibroblasts: Morphology and IgE-mediated release of histamine, prostaglandin D2, and leukotrienes. J Immunol 1987;139(2):494-500.

(269) Stevens RL, Rothenberg ME, Levi-Schaffer F, Austen KF. Ontogeny of in vitro-differentiated mouse mast cells. Fed Proc 1987;46(5):1915-1919.

(270) Levi-Schaffer F, Austen KF, Gravallese PM, Stevens RL. Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A 1986;83(17):6485-6488.

(271) Marikovsky M, Levi-Schaffer F, Arnon R, Fishelson Z. Schistosoma mansoni: Killing of transformed schistosomula by the alternative pathway of human complement. Exp Parasitol 1986;61(1):86-94.

(272) Levi-Schaffer F, Tarrab-Hazdai R, Arnon R, Smolarsky M. A novel lipid-conjugated marker for the direct labeling of the schistosomulum membrane. Am J Trop Med Hyg 1986;35(3):544-548.

(273) Hazdai RT, Levi-Schaffer F, Brenner V, Horowitz S, Eshhar Z, Arnon R. Protective monoclonal antibody against Schistosoma mansoni: Antigen isolation, characterization, and suitability for active immunization. J Immunol 1985;135(4):2772-2779.

(274) Levi-Schaffer F, Austen KF, Caulfield JP, Hein A, Bloes WF, Stevens RL. Fibroblasts maintain the phenotype and viability of the rat heparin-containing mast cell in vitro. J Immunol 1985;135(5):3454-3462.

(275) Tarrab-Hazdai R, Levi-Schaffer F, Gonzales G, Arnon R. Acetylcholinesterase of Schistosoma mansoni. Molecular forms of the solubilized enzyme. Biochim Biophys Acta Protein Struct Mol Enzymol 1984;790(1):61-69.

(276) Levi-Schaffer F, Tarrab-Hazdai R, Schryer MD, Arnon R, Smolarsky M. Isolation and partial characterization of the tegumental outer membrane of schistosomula of Schistosoma mansoni. Mol Biochem Parasitol 1984;13(3):283-300.

(277) Levi-Schaffer F, Tarrab-Hazdai R, Meshulam H, Arnon R. Effect of phosphonium salts and phosphoranes on the acetylcholinesterase activity and on the viability of Schistosoma mansoni parasites. Int J Immunopharmacol 1984;6(6):619-627.

(278) Tarrab‐Hazdai R, Levi‐Schaffer F, Smolarsky M, Arnon R. Acetylcholinesterase of Schistosoma mansoni: antigenic cross‐reactivity with Electrophorus electricus and its functional implications. Eur J Immunol 1984;14(3):205-209.

(279) Levi Schaffer F, Schryer MD, Tarrab Hazdai R, Smolarsky M. A method of introducing lipid-conjugated antigens into the surface of schistosomula. Am J Trop Med Hyg 1983;32(2):343-349.

(280) Levi-Schaffer F, Schryer MD, Somlarsky M. The resistance of schistosomula of Schistosoma mansoni to antibodies and complement in vitro does not correlate with the binding of antibodies to the surface of the parasite. J Immunol 1982;129(6):2744-2751.

(281) Levi-Schaffer F, Bernstein A, Meshorer A, Arnon R. Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat Rep 1982;66(1):107-114.

(282) Levi-Schaffer F, Smolarsky M. Schistosoma mansoni: Effect of insulin and a low-molecular-weight fraction of serum on schistosomula in chemically defined media. Exp Parasitol 1981;52(3):378-385.